Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment

被引:0
作者
Maximilian Fleischmann
Ulf Schnetzke
Karin G. Schrenk
Volker Schmidt
Herbert G. Sayer
Inken Hilgendorf
Andreas Hochhaus
Sebastian Scholl
机构
[1] Universitätsklinikum Jena,Klinik für Innere Medizin II (Abteilung Hämatologie und Internistische Onkologie)
[2] HELIOS Klinikum Erfurt,undefined
来源
Journal of Cancer Research and Clinical Oncology | 2017年 / 143卷
关键词
AML; FLT3-ITD; Allogeneic transplantation; Tyrosine kinase inhibitor;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:337 / 345
页数:8
相关论文
共 603 条
[1]  
Badar T(2015)Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade Am J Hematol 90 1065-1070
[2]  
Kantarjian HM(2008)Acute GvHD: pathogenesis and classification Bone Marrow Transplant 41 S58-S64
[3]  
Nogueras-Gonzalez GM(2007)Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML Blood 109 2264-2265
[4]  
Borthakur G(2009)A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML Blood 113 4063-4073
[5]  
Garcia Manero G(2009)Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition Cytogenetic and Genome Research 127 1-4
[6]  
Andreeff M(2012)Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis J Clin Oncol 30 735-741
[7]  
Konopleva M(2012)Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm–combined prospective analysis by the German AML Intergroup J Clin Oncol 30 3604-3610
[8]  
Kadia TM(2013)Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia N Engl J Med 368 2059-2074
[9]  
Daver N(2012)Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning Bone Marrow Transplant 47 1171-1177
[10]  
Wierda WG(2016)A phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia: a therapeutic advances in childhood leukemia & lymphoma (TACL) study Clin Cancer Res 22 4014-4022